Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TALS

Talaris Therapeutics (TALS) Stock Price, News & Analysis

Talaris Therapeutics logo

About Talaris Therapeutics Stock (NASDAQ:TALS)

Advanced Chart

Key Stats

Today's Range
$21.49
$23.70
50-Day Range
$12.36
$28.36
52-Week Range
$0.89
$27.95
Volume
622,555 shs
Average Volume
386,531 shs
Market Capitalization
$970.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TALS Stock News Headlines

Tourmaline Bio, Inc. (TRML)
AI Frenzy Could Send ‘EarnPhone’ Soaring
The hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and searches — are feeding the next wave of AI innovation. Big Tech is harvesting it. Mode Mobile is giving it back to you. They are creating a user-powered data economy that shares the upside, and +50M users have already generated +$325M in earnings. This isn't a theory… Mode’s 32,481% revenue growth from 2019-2022 landed them the #1 spot on Deloitte’s 2023 list of fastest growing companies in software, and they’ve secured the Nasdaq ticker $MODE ahead of a potential IPO. The offering could close any moment now. AI breakthroughs are everywhere, but these models need your data to survive. Invest in the company that allows you to share in the profits from yours.
Longitude Venture Partners III, L.P.'s Net Worth
See More Headlines

TALS Stock Analysis - Frequently Asked Questions

Talaris Therapeutics, Inc. (NASDAQ:TALS) announced its quarterly earnings results on Friday, November, 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03.

Talaris Therapeutics (TALS) raised $150 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Talaris Therapeutics investors own include Graphite Bio (GRPH), Vaccitech (VACC), Achilles Therapeutics (ACHL), Allogene Therapeutics (ALLO), Cytec Industries (CYT), Immunocore (IMCR) and Century Therapeutics (IPSC).

Company Calendar

Last Earnings
11/12/2021
Today
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TALS
CIK
1827506
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$73.89 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.93%
Return on Assets
-37.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.41
Quick Ratio
15.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.33 per share
Price / Book
5.24

Miscellaneous

Outstanding Shares
42,764,000
Free Float
35,708,000
Market Cap
$970.32 million
Optionable
Not Optionable
Beta
2.18

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:TALS) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners